

MAR 05 2003
TECH CENTER 1600/2900

1646

Please type a plus sign (+) inside this box →



PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/819,094	
	Filing Date	March 27, 2001	
	First Named Inventor	WEINER, RICHARD I.	
	Group Art Unit	1646	
	Examiner Name	BRANNOCK, MICHAEL T.	
Total Number of Pages in This Submission	6	Attorney Docket Number	UCSF-264CON

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): return receipt postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Signing Attorney/Agent (Reg. No.)	KARL BOZICEVIC, 28,807
Signature	
Date	February 26, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: February 26, 2003.	
Typed or printed name	Kimberly Williams Zuehlke
Signature	
Date	February 26, 2003

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

#15C/Pur



CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.			
Typed or Printed Name	Kimberly Williams Zuehlke		
Signature	<i>Kimberly W Zuehlke</i>	Date	26 February 2003
AMENDMENT UNDER 37 C.F.R. §1.111 Address to: Assistant Commissioner for Patents Washington, D.C. 20231	Attorney Docket No.	UCSF-264CON	
	Confirmation No.	6968	
	First Named Inventor	WEINER, RICHARD I.	
	Application Number	09/819,094	
	Filing Date	March 27, 2001	
	Group Art Unit	1646	
	Examiner Name	BRANNOCK, MICHAEL T.	
	Title:	"NOVEL ANTIANGIOGENIC PEPTIDE AGENTS AND THEIR THERAPEUTIC AND DIAGNOSTIC USE"	

Sir:

This amendment is responsive to the Office Action dated November 26, 2002 for which a three-month period for response was given making this response due on or before February 26, 2003. In view of the amendments to the claims and the remarks put forth below, reconsideration and allowance are respectfully requested.

AMENDMENTS

RECEIVED

MAR 05 2003

IN THE CLAIMS

TECH CENTER 1600/2900

Please cancel claims 1-5, 27, 29 and 30 from the application without prejudice. Please amend claim 28 as shown below and as shown on the attached "Version with Markings to Show Changes Made."

C¹ 28. (Amended) An isolated peptide having an amino acid sequence of SEQ ID NO:18 present in a pharmaceutically acceptable carrier.